Fact Sheet

Second Quarter 2011 *Issued July 27, 2011*www.tevapharm.com

CONTACT INFORMATION: Elana Holzman Tel +972-3-926-7554, E-mail: elana.holzman@teva.co.il Kevin Mannix Tel (215) 591-8912, E-mail: kevin.mannix@tevausa.com

Company Overview

Teva Pharmaceutical Industries Ltd., is among the top 15 pharmaceutical companies in the world and the leader in generic pharmaceuticals, specializing in development, production and marketing of a wide range of generic, innovative and branded pharmaceuticals, biogenerics and active pharmaceutical ingredients. Teva currently operates in about 60 countries with some 40,000 employees worldwide. Its innovative R&D efforts focus on therapies for the central nervous system (with emphasis

on multiple sclerosis), autoimmune diseases and oncology. Teva differentiates itself by balancing its portfolio with generic, innovative and branded products, vertically integrating its pharmaceutical and API activities, combining local customer responsiveness with a "global edge", and by its global footprint. Teva's success lies in the leadership of its management, the skills and devotion of its people, the quality of its offerings and its focus on customers and patients.

Net Sales (U.S. \$ in Millions)




Market Data (As of July 26, 2011)

Stock Symbol	TEVA
Closing Price	\$46.79
52 Week Range	\$44.86 - \$57.08
Market Capitalization	\$44 billion
#14 in NASDAQ-100	


NASDAQ-100




Net Income^(1,2) (U.S. \$ in Millions)




Stock Chart (As of July 26, 2011)



Earning Per Share^(1,2) (u.s. \$)



R&D Expenses (net) (u.S. \$ in Millions)



Recent Events

July 14, 2011 - Teva announced that it has completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for \$934 million in cash. Taiyo is the third largest generics manufacturer in Japan with sales of approximately \$530 million in 2010. Taiyo brings to Teva a portfolio of over 550 products and a strong presence in all major channels in the Japanese pharmaceutical market. Teva also gained access to Taiyo's strong R&D team, local regulatory expertise and a state of the art production facility. Following the acquisition, Teva expects to reach \$1 billion in sales in Japan, ahead of its original 2015 target. The transaction was funded through a combination of cash on hand and bank debt.

June 13, 2011 - Teva announced that it has entered into Syndicated Credit Facilities totaling \$4 billion supporting the \$6.8 billion acquisition of Cephalon, Inc.

June 6, 2011 - Teva announced that lipegfilgrastim (INN; internal code - XM22), a long acting granulocyte colony-stimulating factor (G-CSF), achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim compared to pegfilgrastim (Amgen's Neulasta™). Worldwide sales in 2010 of G-CSF totaled \$4.2 billion, of which Neulasta™ sales represented \$3.56 billion.

June 2, 2011 - Teva announced completion of patient enrollment for the GALA (Glatiramer Acetate Low-frequency Administration) trial. This international Phase III trial in patients with RRMS, is designed to examine the efficacy, safety and tolerability of 40mg COPAXONE® (glatiramer acetate

injection) administered 3 times a week compared to placebo. The primary endpoint of the trial is the total number of confirmed relapses during a 12-month placebo-controlled phase, which will be followed by an open-label extension phase. Patient enrollment was completed in May 2011, recruiting over 1,400 patients at 180 sites in the U.S., Europe, Central Eastern Europe and Israel. Results from the trial are expected in the second quarter of 2012.


May 31, 2011 - Teva announced today that patent litigation with Pfizer Inc. related to generic versions of Pfizer's Neurontin® (gabapentin) capsules and tablets sold by Teva and its subsidiary IVAX Pharmaceuticals has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties, which provides for a full release of Teva and its subsidiaries. The financial terms of the settlement are confidential.

May 26, 2011 - Teva announced that the FDA has granted approval for the Company's ANDA to market a generic version of ViiV Healthcare Company's HIV treatment, Combivir Tablets (Lamivudine and Zidovudine). Shipment is expected to commence during the fourth quarter 2011, as per the terms of a settlement agreement between Teva and Glaxo Group Ltd. and ViiV Healthcare. The brand product had annual sales of approximately \$315 million in the U.S., based on IMS sales data. As the first company to file an ANDA containing paragraph IV certification for these products, the FDA has determined that Teva is eligible for a 180-day period of marketing exclusivity.

Sales by Region



COPAXONE® Global In-Market Sales (u.s. \$ in Millions)



U.S. Generic Pipeline (As of July 12, 2011)

185 ANDAs Over \$116 billion in total branded sales
126 Paragraph IV filings
77 First-to-File

Over \$54 billion in total branded sales

Branded Pharmaceuticals - Pipeline



TV-1101 (OGX-011)
Prostate Cancer 1st line (Phase III)
TV-1101 (OGX-011)
Prostate Cancer 2nd line (Phase III)
TV-1101 (OGX-011)
Lung Cancer (Phase III)
DiaPep-277 - Type I Diabetes (Phase III)
Laquinimod - Crohn's disease (Phase II)
CT-011 - Hemato - Oncological
(Phase II)
CT-011 - Solid Tumor Oncology (Phase II)
Laquinimod - Lupus (Phase II)
Laquinimod - Lupus (Phase II)
Albuterol Spiromax
Asthma (CPP (Phase II)
FP Spiromax - Asthma (Phase III)
Vaginal Ring (undisclosed)
Menopause product (undisclosed)
Rituximab (Phase III)
2 Biosimilars projects (undisclosed)
End Phase III 2012-2015

* File submitted in EMA; ** Phase III completed in perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

Selected U.S. Generic Approvals (May - July 2011)

Product		Approval/	Branded Product		Indication
		Launch Date	Name	Market size (U.S. \$ in Millions)	mulcution
Eszopiclone	Tablets	5/23/2011	Lunesta®	794	Treatment of insomnia
Lamivudine/Zidovudine	Tablets	5/25/2011	Combivir®	313	Treatment of HIV-1 infection
Donepezil HCl (1)	Tablets	5/31/2011	Aricept®	2,303	Treatment of dementia of the Alzheimer's type
Letrozole (1)	Tablets	6/3/2011	Femara®	702	Chemotherapy (breast cancer)
Levofloxacin (1)	Tablets	6/20/2011	Levaquin®	1,573	Antibiotic
Amlodipine/Benazepril (1)	Capsules	7/5/2011	Lotrel®	290	Treatment of hypertension